Related Experiment Video

Updated: Apr 15, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

Tucatinib alleviates postmenopausal osteoporosis by suppressing osteoclast differentiation via regulating the

Xin Liu1, Shuang Liu1, Guoqiang Xu1

  • 1State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, 250012, China.

Biochemical Pharmacology
|April 13, 2026
PubMed

Insights

Tucatinib, a potent Cathepsin K (CTSK) inhibitor, effectively treats postmenopausal osteoporosis by suppressing bone resorption and preventing bone loss in mouse models. It offers a dual-action therapeutic strategy by targeting both CTSK and the DRP1/NFATc1 axis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cell Biology

Background:

  • Postmenopausal osteoporosis (PMOP) is a widespread metabolic bone disease.
  • Cathepsin K (CTSK) is a crucial target for PMOP therapy due to its role in bone resorption.

Purpose of the Study:

  • To identify and validate Tucatinib as a potent inhibitor of CTSK for PMOP treatment.
  • To elucidate the dual-action mechanism of Tucatinib in alleviating osteoporotic bone loss.

Main Methods:

  • Structure-based virtual screening and functional validation.
  • In vitro assays including MST, molecular docking, and CTSK activity assays.
  • In vivo studies using ovariectomized mouse models.

Main Results:

  • Tucatinib was identified as a potent CTSK inhibitor, directly binding and suppressing osteoclast-mediated bone resorption.
  • Tucatinib attenuated osteoclast differentiation and prevented bone loss in ovariectomized mice.
  • Tucatinib maintained mitochondrial homeostasis by inhibiting DRP1 phosphorylation and reducing mtROS, stabilizing mitochondrial dynamics and suppressing NFATc1 activation.

Conclusions:

  • Tucatinib demonstrates a dual-action therapeutic strategy for PMOP by inhibiting CTSK and modulating the DRP1/NFATc1 axis.
  • Tucatinib effectively alleviates osteoporotic bone loss through simultaneous targeting of key pathways.
Keywords:
CTSKDRP1NFATc1OsteoclastTucatinib

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.3K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K